Ken Griffin Janux Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$35.12 - $64.78 $414,415 - $764,404	-11,800 Reduced 86.76%	1,800 $75,000
Q1 2024 May 15, 2024	BUY	$7.93 - $49.75 $63,440 - $398,000	8,000 Added 142.86%	13,600 $512,000
Q4 2023 Feb 14, 2024	BUY	$5.85 - $11.7 $18,720 - $37,440	3,200 Added 133.33%	5,600 $60,000
Q3 2023 Nov 14, 2023	SELL	$9.56 - $14.0 $138,620 - $203,000	-14,500 Reduced 85.8%	2,400 $24,000
Q2 2023 Aug 14, 2023	SELL	$11.08 - $15.92 $390,016 - $560,384	-35,200 Reduced 67.56%	16,900 $200,000
Q1 2023 May 15, 2023	SELL	$11.25 - $22.21 $88,875 - $175,459	-7,900 Reduced 13.17%	52,100 $630,000
Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $666,000 - $1.1 Million	60,000 New	60,000 $790,000

160

37.2M

70.4K

101K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.27B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.